Compare RFI & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RFI | LCTX |
|---|---|---|
| Founded | 1992 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.3M | 251.4M |
| IPO Year | N/A | 1996 |
| Metric | RFI | LCTX |
|---|---|---|
| Price | $10.43 | $0.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 101.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $4.38 |
| Revenue Next Year | N/A | $10.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $10.25 | $0.88 |
| 52 Week High | $12.07 | $2.09 |
| Indicator | RFI | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 50.66 |
| Support Level | $10.25 | $0.88 |
| Resistance Level | $10.56 | $1.05 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 38.52 | 68.16 |
Cohen & Steers Total Return Realty Fund Inc is a diversified closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.